StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value
$11.62+0.72 (+6.61%)

Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –

Fennec Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Fennec Pharmaceuticals's cash was $48.68M at Sep 30, 2026. For fiscal 2025 it was $36.79M, up 38.1% from the year before. Over ten years it grew 44.3% a year on average. The highest annual figure on record is $678.00M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$36.79M+38.1%
FY2024Dec 31, 2024$26.63M+100.7%
FY2023Dec 31, 2023$13.27M-44.2%
FY2022Dec 31, 2022$23.77M+7644.0%
FY2021Dec 31, 2021$307.00K+3737.5%
FY2020Dec 31, 2020$8.00K-100.0%
FY2019Dec 31, 2019$678.00M+2876.2%
FY2018Dec 31, 2018$22.78M-19.4%
FY2017Dec 31, 2017$28.26M+619.8%
FY2016Dec 31, 2016$3.93M+316.8%
FY2015Dec 31, 2015$942.00K-59.2%
FY2014Dec 31, 2014$2.31M+38.7%
FY2013Dec 31, 2013$1.66M-27.8%
FY2012Dec 31, 2012$2.30M-56.5%
FY2011Dec 31, 2011$5.30M-10.9%
FY2010Dec 31, 2010$5.95M+768.2%
FY2009Dec 31, 2009$685.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$48.68M+121.8%
Q2 FY2026Jun 30, 2026$41.25M+120.5%
Q1 FY2026Mar 31, 2026$40.18M+77.2%
Q4 FY2025Dec 31, 2025$36.79M+38.1%
Q3 FY2025Sep 30, 2025$21.95M-45.6%
Q2 FY2025Jun 30, 2025$18.71M-56.6%
Q1 FY2025Mar 31, 2025$22.68M-55.7%
Q4 FY2024Dec 31, 2024$26.63M+100.7%
Q3 FY2024Sep 30, 2024$40.32M+225.2%
Q2 FY2024Jun 30, 2024$43.05M+187.8%
Q1 FY2024Mar 31, 2024$51.18M+178.3%
Q4 FY2023Dec 31, 2023$13.27M-44.2%
Q3 FY2023Sep 30, 2023$12.40M-58.3%
Q2 FY2023Jun 30, 2023$14.96M+0.3%
Q1 FY2023Mar 31, 2023$18.39M+0.7%
Q4 FY2022Dec 31, 2022$23.77M+7644.0%
Q3 FY2022Sep 30, 2022$29.75M+22.3%
Q2 FY2022Jun 30, 2022$14.92M-45.4%
Q1 FY2022Mar 31, 2022$18.26M-31.7%
Q4 FY2021Dec 31, 2021$307.00K+3737.5%
Q3 FY2021Sep 30, 2021$24.34M-26.6%
Q2 FY2021Jun 30, 2021$27.29M-29.5%
Q1 FY2021Mar 31, 2021$26.75M+170.2%
Q4 FY2020Dec 31, 2020$8.00K-100.0%
Q3 FY2020Sep 30, 2020$33.17M+117.6%
Q2 FY2020Jun 30, 2020$38.73M+183.7%
Q1 FY2020Mar 31, 2020$9.90M-51.1%
Q4 FY2019Dec 31, 2019$678.00M+2876.2%
Q3 FY2019Sep 30, 2019$15.24M-37.9%
Q2 FY2019Jun 30, 2019$13.65M-46.8%
Q1 FY2019Mar 31, 2019$20.23M-24.3%
Q4 FY2018Dec 31, 2018$22.78M-19.4%
Q3 FY2018Sep 30, 2018$24.52M+153.1%
Q2 FY2018Jun 30, 2018$25.64M+150.6%
Q1 FY2018Mar 31, 2018$26.72M+721.9%
Q4 FY2017Dec 31, 2017$28.26M+619.8%
Q3 FY2017Sep 30, 2017$9.69M–
Q2 FY2017Jun 30, 2017$10.23M–
Q1 FY2017Mar 31, 2017$3.25M–
Q4 FY2016Dec 31, 2016$3.93M–

More Fennec Pharmaceuticals figures

See a number that looks wrong?